

Project Title: Japanese risk prediction model: Risk prediction model including therapeutic options in IgA nephropathy

Primary investigator: Yusuke Suzuki (Juntendo University Faculty of Medicine), Hitoshi Suzuki (Juntendo University Urayasu Hospital), Keiichi Matsuzaki (Kitasato University School of Medicine)

Brief Description:

Recently derived prediction model for kidney outcome of IgA nephropathy (IgAN) based on clinical and pathological predictor variables from multi-ethnic cohorts (Barbour SJ, JAMA Intern Med. 2019, Kidney Int. 2022) is a potentially valuable tool in terms of its application to daily clinical practice as well as for clinical trial design. In Japan, school-aged children and adults undergo routine annual screenings for urinary abnormalities; nephrologists can provide early-stage therapeutic interventions. Thus, we need the original prediction model, including the therapeutic options. In this project, we aim to derived and validated model to be used after renal biopsy with therapeutic options in Japanese patients.

Project status:

As presented at ERA 2026, we externally validated the International IgAN Risk Prediction Tool using the Japanese J-IGACS cohort (“External Validation of the International IgA Nephropathy Risk Prediction Tool: A Comparison of Baseline and 1-Year post biopsy Models using J-IGACS”). We found that the 1-year post-biopsy model showed substantially better prognostic performance than the baseline model in Japanese patients (C-statistics: Baseline model 0.55, 1-year post biopsy model 0.77). Based on these findings, we are currently rebuilding the prognostic model for Japanese patients using the Oxford classification.

Founding Source: Grant-in-Aid for Progressive Renal Diseases Research, Research on Rare and Intractable Disease, from the Ministry of Health, Labour and Welfare of Japan.

Preliminary publication: none